Camber Capital filed an amended 13G on Protalix BioTherapeutics (NYSE: PLX ) today disclosing a large increase in its position. Stephen Dubois' hedge fund had 9 million shares of Protalix at the end of June. The amended filing shows a position of 14.8 million shares corresponding to a 15.59% stake in the company.